The main risk is value capture, not technical relevance. Arm is likely to matter more in the AI stack by 2031, but supply limits,
export controls,
RISC-V substitution and customer pushback could keep that importance from translating into enough incremental dollars. Because the stock starts from a very high valuation, even strong revenue growth can still produce only moderate shareholder returns if multiples normalize.